In this study, the PTEN difference-identified model we constructed showed higher accuracy than TIDE in distinguishing patient outcomes and ICB response in an immunotherapy cohort of metastatic urothelial cancer and metastatic melanoma. Here, PTEN is linked to metastatic melanoma.